HK1047038A1 - 用於治疗神经变性的方法 - Google Patents

用於治疗神经变性的方法 Download PDF

Info

Publication number
HK1047038A1
HK1047038A1 HK02108589.8A HK02108589A HK1047038A1 HK 1047038 A1 HK1047038 A1 HK 1047038A1 HK 02108589 A HK02108589 A HK 02108589A HK 1047038 A1 HK1047038 A1 HK 1047038A1
Authority
HK
Hong Kong
Prior art keywords
stroke
nefiracetam
patient
treatment
neurodegeneration
Prior art date
Application number
HK02108589.8A
Other languages
English (en)
Chinese (zh)
Inventor
大友英一
高须良之
高須良之
Original Assignee
第一制药株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一制药株式会社 filed Critical 第一制药株式会社
Publication of HK1047038A1 publication Critical patent/HK1047038A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HK02108589.8A 2000-02-23 2001-02-23 用於治疗神经变性的方法 HK1047038A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51195200A 2000-02-23 2000-02-23
US09/511,952 2000-02-23
PCT/JP2001/001342 WO2001062246A1 (en) 2000-02-23 2001-02-23 Method for treating neurodegeneration

Publications (1)

Publication Number Publication Date
HK1047038A1 true HK1047038A1 (zh) 2003-02-07

Family

ID=24037094

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108589.8A HK1047038A1 (zh) 2000-02-23 2001-02-23 用於治疗神经变性的方法

Country Status (20)

Country Link
US (2) US6423739B1 (enExample)
EP (1) EP1171123B1 (enExample)
JP (1) JP2003523385A (enExample)
KR (1) KR20010110798A (enExample)
CN (1) CN1362877A (enExample)
AR (1) AR030551A1 (enExample)
AT (1) ATE336246T1 (enExample)
AU (1) AU784418B2 (enExample)
BR (1) BR0104586A (enExample)
CA (1) CA2368352C (enExample)
DE (1) DE60122252T2 (enExample)
DK (1) DK1171123T3 (enExample)
ES (1) ES2270981T3 (enExample)
HK (1) HK1047038A1 (enExample)
ID (1) ID30377A (enExample)
IL (1) IL145799A (enExample)
MX (1) MXPA01010749A (enExample)
NO (1) NO321911B1 (enExample)
TW (1) TWI289060B (enExample)
WO (1) WO2001062246A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
EP1356812B1 (en) * 2000-12-28 2009-05-13 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
JP2005501108A (ja) * 2001-08-22 2005-01-13 第一製薬株式会社 神経変性治療におけるネフィラセタムの使用
RU2205631C1 (ru) * 2002-06-19 2003-06-10 Закрытое акционерное общество "Брынцалов-А" Ноотропное средство "ноотобрил" в форме таблеток
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US8962676B2 (en) 2009-10-22 2015-02-24 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with CNS or PNS demyelination
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469995A (en) * 1946-07-23 1949-05-10 Schaul Martin Carl Process for the production of food preparations from potatoes and similar farinaceoustubers
US3031314A (en) * 1960-03-16 1962-04-24 Carl E Hendel Preparation of dehydrated potatoes
US3260607A (en) * 1961-02-07 1966-07-12 Canadian Patents Dev Preparation of dehydrated cooked mashed potato
US3968265A (en) * 1973-02-01 1976-07-06 American Potato Company Freeze-thaw stable, french fry potato product and process for producing the same
DE2923975A1 (de) 1979-06-13 1980-12-18 Nattermann A & Cie Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE2924011C2 (de) 1979-06-13 1982-04-08 A. Nattermann & Cie GmbH, 5000 Köln Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten
IT1141287B (it) 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
SK279285B6 (sk) 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5525058A (en) 1992-03-27 1996-06-11 American Dental Technologies, Inc. Dental treatment system
WO1997003485A1 (en) 1995-07-10 1997-01-30 Kodera Electronics Co., Ltd. Device for inserting wire to be worked
US6107330A (en) 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
NZ333978A (en) 1996-07-30 2000-09-29 Henkel Ecolab Gmbh & Co Film-building agent for protecting teats and udders against infection after milking, comprising a film-forming component and disinfecting agents
AU727482B2 (en) 1996-10-01 2000-12-14 Daiichi Pharmaceutical Co., Ltd. Mitochondrial membrane stabilizer
US6211701B1 (en) 1996-12-16 2001-04-03 Rose Research, Llc Low power line switching circuit, device and method
IT1293533B1 (it) 1997-07-14 1999-03-01 Angeletti P Ist Richerche Bio Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che
AU8131198A (en) 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
AR020115A1 (es) 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
CN1368882A (zh) 1999-05-31 2002-09-11 第一制药株式会社 神经元死亡抑制剂

Also Published As

Publication number Publication date
NO321911B1 (no) 2006-07-17
US20010051653A1 (en) 2001-12-13
CN1362877A (zh) 2002-08-07
CA2368352C (en) 2009-11-10
MXPA01010749A (es) 2002-08-20
DE60122252T2 (de) 2007-07-05
AU3414501A (en) 2001-09-03
NO20015162D0 (no) 2001-10-22
ID30377A (id) 2001-11-29
KR20010110798A (ko) 2001-12-13
US6399650B2 (en) 2002-06-04
US20020055534A1 (en) 2002-05-09
IL145799A (en) 2006-10-31
DK1171123T3 (da) 2006-12-04
CA2368352A1 (en) 2001-08-30
US6423739B1 (en) 2002-07-23
ATE336246T1 (de) 2006-09-15
EP1171123A1 (en) 2002-01-16
DE60122252D1 (de) 2006-09-28
EP1171123B1 (en) 2006-08-16
NO20015162L (no) 2001-12-21
WO2001062246A1 (en) 2001-08-30
TWI289060B (en) 2007-11-01
ES2270981T3 (es) 2007-04-16
JP2003523385A (ja) 2003-08-05
BR0104586A (pt) 2002-01-08
AR030551A1 (es) 2003-08-27
IL145799A0 (en) 2002-07-25
AU784418B2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
KR101125462B1 (ko) 모다피닐의 제약 제제
AU706735B2 (en) Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy- carbonylaminobenzene for prophylaxis and treatment of sequelae of acute and chronic reduced circulation in the brain and neurodegenerative disorders
RU2396982C2 (ru) Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
EP3064206B1 (en) Treatment of huntington's disease using laquinimod
US20080076820A1 (en) Method for treating neurodegeneration
US20040029941A1 (en) Zonisamide use in obesity and eating disorders
EP1435943B1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia
HUE024558T2 (hu) Biotin alkalmazása szklerózis multiplex kezelésére
HK1047038A1 (zh) 用於治疗神经变性的方法
JPWO2002053153A1 (ja) 神経因性疼痛治療及び予防薬
IL309770A (en) NK1 antagonist combination and a method for the treatment of synucleinopathies
RU2321398C2 (ru) Способ лечения
KR20010105418A (ko) 기분 장애 치료용 오사네턴트
PT95698B (pt) Processo para a preparacao de composicoes farmaceuticas contendo aril-alquilamidas utilizadas no tratamento de doencas neurodegenarativas
JP2004155661A (ja) 突然死予防剤
EA012443B1 (ru) Фармацевтическая композиция, включающая 1-(3-хлорфенил)-3-алкилпиперазин, для лечения расстройств аппетита